PhaseV to Showcase Cutting-Edge AI/ML Innovations for Clinical Trials at Major Biopharma Conferences
PhaseV to Present at Key Biopharma Conferences
PhaseV is set to make a significant appearance at several upcoming biopharma conferences, emphasizing its leadership in the realm of artificial intelligence (AI) and machine learning (ML) for clinical development. These events play a crucial role in shaping the dialogue surrounding clinical trial methodologies and execution within the industry.
Shaping the Future of Clinical Trials
Raviv Pryluk, PhD, the CEO and Co-founder of PhaseV, stated, "Clinical trials are inherently complex and uncertain. By combining Bayesian statistical frameworks with advanced AI-driven simulation, we help sponsors reduce risk and accelerate their path to market." This innovative approach demonstrates how PhaseV is not only adapting to the changing landscape of clinical trials but also setting the standard with its pioneering technologies.
The company’s participation at these conferences will showcase its research capabilities and foster essential discussions within the biopharma community. PhaseV intends to illustrate how its next-generation Bayesian and causal AI solutions enhance the flexibility, robustness, and speed of clinical trials, enabling quicker access to vital medications and therapies for patients.
Upcoming Events
Pharma Tech Forum - Advancing Biotech with Computation
Date: September 17, 2025
Location: Tel Aviv, Israel
During this event, PhaseV’s CTO, Elad Berkman, will join a panel of biotechnology leaders to discuss the transition from vision to implementation in biotech projects.
ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop (RISW 2025)
Date: September 24-26
Location: Rockville, MD, USA
PhaseV executives will present findings regarding computing, optimization, and causal inference relevant for adaptive clinical trials.
Fierce Biotech Week
Date: October 7-9, 2025
Location: Boston, MA, USA
A panel moderated by Raviv Pryluk will focus on innovations in clinical design and management, addressing broader trends and future direction in clinical development.
Bayesian Biostatistics Conference - Bayes
Date: October 22-24, 2025
Location: Leiden, The Netherlands
At this conference, PhaseV will present on optimal Bayesian adaptive sequential trial design using Stepwise Monte Carlo methods, showcasing the enhanced flexibility and robustness these approaches offer.
About PhaseV's Innovations
PhaseV is at the forefront of integrating advanced AI/ML solutions to optimize the clinical development process. The company is dedicated to supporting biopharma sponsors and Contract Research Organizations (CROs) in rapidly designing clinical trials that are both adaptive and Bayesian. Their platform has proven its value significantly: by reducing trial costs by half, decreasing enrollment sizes and durations by 40%, and improving the chances of trial success by more than 30%.
To date, PhaseV has successfully delivered results across diverse therapeutic areas, including neurology, oncology, immunology, gastrointestinal diseases, and rare conditions. With a commitment to revolutionizing clinical trial processes, PhaseV aims to provide timely access to new treatments that can save and improve lives.
For further details, visit PhaseV Trials and follow their updates on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.